COTA Signs Agreement with FDA for Breast Cancer Research
The agreement will bring real-world data to cancer treatment development.
Compounding Pharmacy Ordered to Cease Operations
After several manufacturing and sterility issues, a permanent injunction has been issued against a Pharm D Solutions, LLC.
Morris & Dickson Settle for $22 Million for Failing to Report Suspicious Opioid Orders
The action by the U.S. Attorney's Office is the latest in legal and policy maneuvers aimed at ending the opioid epidemic.
ASHP and ASPEN Launch Professional Nutritional Support Certificate
Earn up to 19.25 hours of CE.
Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes.
FDA Approves Vraylar (Cariprazine) for Bipolar Depression
New indication adds to the oral antipsychotic’s portfolio of conditions.
FDA Approves PI3K Inhibitors for Breast Cancer
First PIK3CA inhibitor treatment approved, along with diagnostic test.
New Gene Therapy for Pediatric Spinal Muscular Atrophy Approved by FDA
Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy
DOAC Use Increasing in Nursing Homes
The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.
Atrial Fibrillation Patients Often Overestimate Stroke and Bleeding Risks
Overestimating the bleeding risk of anticoagulants may lead to poor compliance.
FDA Approves Sorilux (Calcipotriene) for Adolescent Plaque Psoriasis
Vitamin D analog foam indicated for topical treatment of plaque psoriasis in teens.
A Closer Look at Sunscreens
Deciding which sunscreen to apply has become a complicated business.
New Corlanor (Ivabradine) Formulation Approved by FDA
Oral solution now approved for adults and pediatric patients.
Generic VESIcare Tablets to Launch in U.S.
Update: now available from three manufacturers.
The Future of Rebates: The Black Swan Scenario
Specialty pharmacy has reached an “inflection point” with the power to change the entire industry model.
FDA Approves Nayzilam (Midazolam) for Seizure Activity in Patients with Epilepsy
Nayzilam is a benzodiazepine antiepileptic nasal spray.
Proposed North Carolina Bill Could Increase Pharmacists' Immunizing Abilities
North Carolina working to expand the number of vaccines pharmacists can administer.
Scientists Are One Step Closer to Needleless Hepatitis B Vaccine
Medical researchers and physicists are collaborating on oral vaccine research.
NACDS and NCPA Issue Joint Statement on Drug Pricing Rule
Both pharmacy groups state that rule should have addressed DIR fees.
Study Finds a Lack of Deprescribing is Harmful and Expensive
Studies indicate a lack of deprescribing is causing physical and fiscal pain to patients.
FDA Approves Fragmin as First Pediatric Anticoagulant Treatment
Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.
FDA Approves Expanded Indication for Venetoclax
Venetoclax, a BCL-2 inhibitor first approved in 2016, is now indicated for chronic lymphocytic leukemia and small lymphocytic lymphoma.
Opinion: Staffing, Phone Lines, and Drive-Throughs
Pete Kreckel discusses how he is always working to improve the workflow in his pharmacy.
New Partnership to Reduce Chronic Drug Shortages
Xellia Pharmaceuticals will manufacture essential antibiotics for Civica Rx.
Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA
Approval marks the first anti-PD-L1 therapy combination for RCC.
Three Red Flags in Pharmacy Cash Flow
With tight margins, DIR fees, generic effective rate fees, and the delay in receiving third-party reimbursements, it’s easy to find yourself faced with cash flow pressures.
44 States Join Lawsuit Alleging Price Fixing for Generics
Suit filed in Connecticut alleges companies conspired to inflate prices on more than 100 generic drugs.
Opioid Prescribing Decrease and Patient Script Abandonment Increase, According to Recent Study
Results from IQVIA Institute for Human Data Science's annual report, "Medicine Use and Spending in the U.S."
CBD Products: Confusion, Hype, and Hope
Despite legal restrictions and insufficient regulation, the market for CBD oil is booming.
FDA Finalizes Guidance on Interchangeability for Biologics
Biosimilar guidance provides “clarity” for drug developers.
